The North America Metabolism Assays Market would witness market growth of 6.9% CAGR during the forecast period (2023-2030).
Metabolism assays are used in life sciences and drug discovery to measure and study various metabolic processes within cells and organisms. These assays are crucial in understanding cellular metabolism, drug screening, toxicity testing, and disease research. The market for metabolism assays includes a wide range of products and services used by researchers in academia, pharmaceutical companies, biotechnology firms, and clinical laboratories.
The pharmaceutical industry's continuous need for new drugs and therapies has driven the demand for metabolism assays. These assays are used in early drug discovery, toxicity testing, and drug screening. As personalized medicine gains traction, there is a growing need for metabolism assays to tailor treatments to patients' metabolic profiles. Ongoing advancements in assay technology, such as high-throughput screening methods and the development of more accurate and sensitive assays, have expanded the market. The growing number of chronic diseases like diabetes and obesity has led to a heightened interest in studying metabolic pathways, fostering growth in the market.
North America has one of the highest prevalences of metabolic disorders, like obesity, diabetes, and cardiovascular diseases. This has led to a strong demand for metabolic assays for diagnosis, monitoring, and management. The aging population in North America is at an increased risk of metabolic disorders. The market continues to grow as healthcare providers, researchers, and patients recognize the critical role of these assays in addressing the challenges posed by chronic diseases. The above factors will boost the market’s growth in this region.
The US market dominated the North America Metabolism Assays Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $644.7 million by 2030. The Canada market is experiencing a CAGR of 9.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.4% during (2023 - 2030).
Based on Product, the market is segmented into Assay Kits & Reagents and Instruments & Analyzers. Based on Application, the market is segmented into Diagnostics (Diabetes, Obesity, Cardiovascular Diseases, Cancer and Others) and Research. Based on Technology, the market is segmented into Colorimetry, Fluorimetry and Spectrometry. Based on End User, the market is segmented into Hospitals, Diagnostics Laboratories and Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., Abcam Plc, Agilent Technologies, Inc, Promega Corporation, Kaneka Eurogentec S.A (Kaneka Corporation), RayBiotech Life, Inc, Sartorius AG, Elabscience Biotechnology Inc. and Bmg Labtech GmbH.
Metabolism assays are used in life sciences and drug discovery to measure and study various metabolic processes within cells and organisms. These assays are crucial in understanding cellular metabolism, drug screening, toxicity testing, and disease research. The market for metabolism assays includes a wide range of products and services used by researchers in academia, pharmaceutical companies, biotechnology firms, and clinical laboratories.
The pharmaceutical industry's continuous need for new drugs and therapies has driven the demand for metabolism assays. These assays are used in early drug discovery, toxicity testing, and drug screening. As personalized medicine gains traction, there is a growing need for metabolism assays to tailor treatments to patients' metabolic profiles. Ongoing advancements in assay technology, such as high-throughput screening methods and the development of more accurate and sensitive assays, have expanded the market. The growing number of chronic diseases like diabetes and obesity has led to a heightened interest in studying metabolic pathways, fostering growth in the market.
North America has one of the highest prevalences of metabolic disorders, like obesity, diabetes, and cardiovascular diseases. This has led to a strong demand for metabolic assays for diagnosis, monitoring, and management. The aging population in North America is at an increased risk of metabolic disorders. The market continues to grow as healthcare providers, researchers, and patients recognize the critical role of these assays in addressing the challenges posed by chronic diseases. The above factors will boost the market’s growth in this region.
The US market dominated the North America Metabolism Assays Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $644.7 million by 2030. The Canada market is experiencing a CAGR of 9.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.4% during (2023 - 2030).
Based on Product, the market is segmented into Assay Kits & Reagents and Instruments & Analyzers. Based on Application, the market is segmented into Diagnostics (Diabetes, Obesity, Cardiovascular Diseases, Cancer and Others) and Research. Based on Technology, the market is segmented into Colorimetry, Fluorimetry and Spectrometry. Based on End User, the market is segmented into Hospitals, Diagnostics Laboratories and Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., Abcam Plc, Agilent Technologies, Inc, Promega Corporation, Kaneka Eurogentec S.A (Kaneka Corporation), RayBiotech Life, Inc, Sartorius AG, Elabscience Biotechnology Inc. and Bmg Labtech GmbH.
Scope of the Study
Market Segments Covered in the Report:
By Product- Instruments & Analyzers
- Assay Kits & Reagents
- Diagnostics
- Diabetes
- Obesity
- Cardiovascular Diseases
- Cancer
- Others
- Research
- Colorimetry
- Fluorimetry
- Spectrometry
- Hospitals
- Diagnostics Laboratories
- Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- Abcam Plc
- Agilent Technologies, Inc
- Promega Corporation
- Kaneka Eurogentec S.A (Kaneka Corporation)
- RayBiotech Life, Inc
- Sartorius AG
- Elabscience Biotechnology Inc
- Bmg Labtech GmbH
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. North America Metabolism Assays Market by Product
Chapter 6. North America Metabolism Assays Market by Application
Chapter 7. North America Metabolism Assays Market by Technology
Chapter 8. North America Metabolism Assays Market by End User
Chapter 9. North America Metabolism Assays Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- Abcam Plc
- Agilent Technologies, Inc
- Promega Corporation
- Kaneka Eurogentec S.A (Kaneka Corporation)
- RayBiotech Life, Inc
- Sartorius AG
- Elabscience Biotechnology Inc
- Bmg Labtech GmbH
Methodology
LOADING...
